PI3K Gamma Inhibitors for Selectivity and Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PI3K gamma inhibitors have less optimal potency, selectivity, and pharmacokinetic properties, necessitating the development of novel inhibitors with improved performance for treating diseases mediated by PI3K gamma activity.
Innovation Solution
Development of compounds of Formula (I) and their pharmaceutically acceptable salts, stereoisomers, or solvates, which exhibit improved selectivity against the PI3Kδ isoform, solubility, and oral bioavailability compared to known inhibitors like IPI-549 and AZ-17.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PI3K gamma inhibitors are used, then PI3K gamma activity is inhibited, but potency and selectivity are suboptimal
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions on the core isoindolinone structure. Different substituents (halogens, alkyl groups, heteroaryl groups) are placed at specific positions to optimize interactions with the PI3K gamma binding pocket, thereby enhancing both potency and selectivity simultaneously
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent type, position, and steric bulk on the isoindolinone core. This allows fine-tuning of the inhibitor's physicochemical properties to achieve optimal binding affinity and selectivity for PI3K gamma over other isoforms
2Reliability
If existing PI3K gamma inhibitors are used, then PI3K gamma activity is inhibited, but pharmacokinetic properties are suboptimal
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by modifying molecular weight, lipophilicity, and hydrogen bonding capacity through strategic substituent selection. These parameter changes improve oral bioavailability and metabolic stability while preserving PI3K gamma inhibition efficacy
3Reliability
If existing PI3K gamma inhibitors are used, then PI3K gamma activity is inhibited, but solubility is suboptimal
Solution Approach 1:
The patent introduces polar substituents and hydrogen bonding groups at specific positions on the isoindolinone core to enhance aqueous solubility. These local modifications maintain the hydrophobic interactions necessary for binding while improving overall solubility properties
Data Source
Figure 1
Figure 2
AI summary
The present disclosure provides selective phosphoinositide 3-kinase gamma inhibitors of Formula (I) including (I-a), (I-b), (I-c), and (I-d), or pharmaceutically acceptable salts thereof. These compounds are useful for the treatment of conditions mediated by one or more PI3K isoforms, such as PI3K gamma (PI3Kγ). The present disclosure further provides methods of inhibiting phosphoinositide 3-kinase gamma using these compounds for treatment of disorders related to phosphatidylinositol 3-kinase gamma activity.